Blue Jet Healthcare shares are likely to remain in focus after the company reported a subdued performance in Q4 FY26, with net profit declining 41.8 per cent year-on-year and revenue falling sharply. The weak earnings have led to a divergence in brokerage views, with analysts maintain a cautious stance amid volatility in core segments, however, remain optimistic about a recovery in FY27 driven by improving demand in contrast media intermediates and pharma intermediates.
Motilal Oswal On Blue Jet Healthcare
Blue Jet Healthcare reported a weak performance for Q4FY26, with net profit falling sharply to Rs 64 crore from Rs 110 crore in the same quarter last year, registering a decline of 41.8 per cent year-on-year.
Revenue for the quarter also saw a significant decline, coming in at Rs 234.7 crore as against RS 340 crore in Q4 FY25, marking a 31 per cent year-on-year fall. The contraction in topline indicates lower business activity or demand challenges, which weighed on the company’s overall financial performance.
Despite the weaker earnings, the company announced a final dividend of Rs 1.20 per share and revealed plans to raise up to Rs 1,000 crore through the issuance of securities. The fundraise is expected to support future growth initiatives and strengthen its financial position going ahead.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
